Chronic Myelogenous Leukemia with the e6a2 BCR-ABL and Lacking Imatinib Response: Presentation of Two Cases

被引：11

作者：

Vefring, Hege K. ^{[1
]}

Gruber, Franz X. E. ^{[3
,4
]}

Wee, Line ^{[1
]}

Hovland, Randi ^{[5
]}

Hjorth-Hansen, Henrik ^{[6
,7
]}

Dahl, Tobias Gedde ^{[8
]}

Meyer, Peter ^{[2
]}

机构：

[1] Stavanger Univ Hosp, Dept Med Biochem, NO-4022 Stavanger, Norway

[2] Stavanger Univ Hosp, Dept Hematol & Oncol, NO-4022 Stavanger, Norway

[3] Univ Tromso, Inst Pharm, Tromso, Norway

[4] Univ Hosp No Norway, Dept Immunol & Transfus Med, Tromso, Norway

[5] Haukeland Hosp, Ctr Med Genet & Mol Med, N-5021 Bergen, Norway

[6] Norwegian Univ Sci & Technol, Univ Trondheim Hosp, St Olavs Hosp, N-7034 Trondheim, Norway

[7] Norwegian Univ Sci & Technol, Inst Canc Res & Mol Med, N-7034 Trondheim, Norway

[8] Univ Hosp, Rikshosp, Dept Internal Med, Unit Hematol & Stem Cell Transplantat, Oslo, Norway

来源：

ACTA HAEMATOLOGICA | 2009年 / 122卷 / 01期

关键词：

BCR-ABL; Chronic myelogenous leukemia; Imatinib; Multiplex RT-PCR; POLYMERASE-CHAIN-REACTION; RESIDUAL DISEASE DETECTION; ACUTE BASOPHILIC LEUKEMIA; CHRONIC-MYELOID-LEUKEMIA; FUSION TRANSCRIPT; CML PATIENT; GENE; IDENTIFICATION; RESISTANCE; DASATINIB;

D O I：

10.1159/000230037

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The BCR-ABL fusion gene represents the hallmark of chronic myelogenous leukemia (CML) and is derived from a translocation between chromosome 9 and 22. The majority of CML patients have a breakpoint in the major BCR region of the BCR gene giving rise to e13a2 or e14a2 BCR-ABL transcripts. Occasionally, other BCR breakpoints occur. The current report describes two e6a2 CML patients with imatinib treatment failure and unusual disease progression. One patient was Philadelphia chromosome positive and one was Philadelphia chromosome negative with an atypical BCR-ABL rearrangement, ins (22; 9). Copyright (C) 2009 S. Karger AG, Basel

引用

页码：11 / 16

页数：6

共 23 条

[1] Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program
Beillard, E
Pallisgaard, N
van der Velden, VHJ
Bi, W
Dee, R
van der Schoot, E
Delabesse, E
Macintyre, E
Gottardi, E
Saglio, G
Watzinger, F
Lion, T
van Dongen, JJM
Hokland, P
Gabert, J
[J]. LEUKEMIA, 2003, 17 (12) : 2474 - 2486
[2] Isolated thrombocytosis as first sign of chronic myeloid leukemia with e6a2 BCR/ABL fusion transcript, JAK2 negativity and complete response to imatinib
Breccia, Massimo
Cannella, Laura
Diverio, Daniela
Streponi, Paola
Nanni, Mauro
Stefanizzi, Caterina
Natalino, Fiammetta
Mecarocci, Sergio
Alimena, Giuliana
[J]. LEUKEMIA RESEARCH, 2008, 32 (01) : 177 - 180
[3] Colla S, 2004, HAEMATOLOGICA, V89, P611
[4] Successful treatment of imatinib-resistant acute megakaryoblastic leukemia with e6a2 BCR/ABL: use of dasatinib and reduced-conditioning stem-cell transplantation
Corm, S.
Renneville, A.
Rad-Quesnel, E.
Grardel, N.
Preudhomme, C.
Quesnel, B.
[J]. LEUKEMIA, 2007, 21 (11) : 2376 - +
[5] CROSS NCP, 1994, LEUKEMIA, V8, P186
[6] e8a2 BCR-ABL: more frequent than other atypical BCR-ABL variants?
Demehri, S
Paschka, P
Schultheis, B
Lange, T
Koizumi, T
Sugimoto, T
Branford, S
Lim, LC
Kegel, T
Martinelli, G
Hochhaus, A
Drucker, BJ
Deininger, MWN
[J]. LEUKEMIA, 2005, 19 (04) : 681 - 684
[7] Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
Druker, Brian J.
Guilhot, Francois
O'Brien, Stephen G.
Gathmann, Insa
Kantarjian, Hagop
Gattermann, Norbert
Deininger, Michael W. N.
Silver, Richard T.
Goldman, John M.
Stone, Richard M.
Cervantes, Francisco
Hochhaus, Andreas
Powell, Bayard L.
Gabrilove, Janice L.
Rousselot, Philippe
Reiffers, Josy
Cornelissen, Jan J.
Hughes, Timothy
Agis, Hermine
Fischer, Thomas
Verhoef, Gregor
Shepherd, John
Saglio, Giuseppe
Gratwohl, Alois
Nielsen, Johan L.
Radich, Jerald P.
Simonsson, Bengt
Taylor, Kerry
Baccarani, Michele
So, Charlene
Letvak, Laurie
Larson, Richard A.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (23) : 2408 - 2417
[8] Identification of E6A2 BCR-ABL fusion in a Philadelphia-positive CML
Dupont, M
Jourdan, E
Chiesa, J
[J]. LEUKEMIA, 2000, 14 (11) : 2011 - 2012
[9] Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia -: A Europe Against Cancer Program
Gabert, J
Beillard, E
van der Velden, VHJ
Bi, W
Grimwade, D
Pallisgaard, N
Barbany, G
Cazzaniga, G
Cayuela, JM
Cavé, H
Pane, F
Aerts, JLE
De Micheli, D
Thirion, X
Pradel, V
González, M
Viehmann, S
Malec, M
Saglio, G
van Dongen, JJM
[J]. LEUKEMIA, 2003, 17 (12) : 2318 - 2357
[10] Identification of an acute basophilic leukaemia carrying a rare e6a2 BCR-ABL transcript
Gregoire, Marie-Jose
Latger-Cannard, Veronique
Staal, Anne
Bologna, Serge
Leotard, Brigitte
Rault, Jean-Philippe
Bery-Dexheimer, Mylene
Jonveaux, Philippe
[J]. ACTA HAEMATOLOGICA, 2006, 116 (03) : 216 - 218

← 1 2 3 →